All News

Recent advances in GI oncology offer new treatment options for colorectal and pancreatic cancers, enhancing patient care and pharmacist roles in management.

Alabama's new law boosts independent pharmacies by ensuring fair PBM reimbursements, while Nevada sets a precedent for expanding pharmacist health care roles.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Discover effective strategies for managing opioid-induced constipation, including the role of PAMORAs and pharmacist involvement in pain management.

Pharmacists play a crucial role in managing headaches in patients on complement inhibitors for PNH, ensuring proper education and risk mitigation strategies.

The FDA intends to update opioid labels to highlight risks of addiction, overdose, and interactions, enhancing safety in pain management practices.

Birelentinib gains FDA fast track designation, offering hope for relapsed CLL/SLL patients resistant to current BTK and BCL2 therapies.

The researchers speculate that this is because of the antioxidant and anti-inflammatory properties of coffee and tea.

The FDA approves dordaviprone, the first systemic therapy for H3 K27M-mutant diffuse midline glioma, offering hope for patients with limited options.

Recommending and administering vaccines is a critical part of medication therapy management.

Designed for use in Celiac disease, larazotide was found to hasten resolution of multisystem inflammatory syndrome symptoms in children with the condition.

The FDA targets 7-hydroxymitragynine, a potent kratom derivative, as a controlled substance due to its opioid-like effects and rising health risks.

Promoting heart health in children reduces obesity and chronic disease risks, ensuring better overall well-being into adulthood.

Amid dropping vaccination rates, pharmacists are key to educating parents and assuaging concerns.

AI-driven analysis reveals guarana offers more sustained cognitive stimulation than caffeine, due to additional bioactive compounds and slower caffeine release kinetics.

Inclisiran was found to have a lower risk of new-onset diabetes compared with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies.

Recent data link a higher consumption of ultraprocessed food to increased lung cancer risk, highlighting the need for dietary changes and further research.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

The FDA expands tocilizumab-anoh's approval for treating cytokine release syndrome (CRS), enhancing treatment options for patients aged 2 and older.

The FDA approved fremanezumab for pediatric migraine prevention, offering a new treatment option for children and adolescents aged 6 to 17 years.

Secretary Robert F. Kennedy Jr announced the cancellation of 22 mRNA vaccine technology investments, alleging the vaccines lacked effectiveness against respiratory diseases.

Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.

The bill promises lower drug costs and greater innovation, but critics still have concerns.

Another bill, another day for the erosion of pharmacy benefits as a means of affording a prescription.

Brad Cochran of Cardinal Health explains the One Voice Initiative, which aims to bolster independent pharmacies.

PHESGO reduced patient infusion time from 90 minutes to as few as 5, enhancing patient experience while maintaining efficacy and safety.

Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.

August marks a pivotal time for oncology pharmacy, blending transitions, celebrations, and new beginnings as professionals prepare for the upcoming season.

Herzuma shows promising efficacy and safety as a cost-effective biosimilar for treating HER2+ advanced gastric cancer, offering new hope for patients.